Company intelligence / Profile preview

Axcan Pharma Inc.

Mont-Saint-Hilaire, Quebec, Canadaorpha.net ↗

Ownership: Private
Employees: ~439
Development stage: Commercial

Overview

Axcan Pharma was a multinational specialty pharmaceutical company focused on gastroenterology with a broad line of prescription products to treat various gastrointestinal diseases and disorders. The company was acquired by TPG Capital in 2008 for approximately US$1.3 billion, later merged with Eurand Pharmaceuticals in 2011 to form Aptalis, which was subsequently acquired by Forest Laboratories in 2014 for $2.9 billion.[3][6][9]

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

itopride hydrochloride

Commercial

Indications: Gastrointestinal diseases

1 more asset in the full pipeline.

Request access →

Partnerships

Gilead SciencesAlthin ABSwedish firm

Beyond the preview

Go deeper on Axcan Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axcan Pharma Inc..

Explore the full profile